Axon Enterprise, Inc $AXON Shares Bought by Ethic Inc.

Key Points

• Ethic Inc. significantly increased its holdings in Axon Enterprise by 90.8% during the second quarter, now owning approximately $3.98 million in shares.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" for Axon, with a target price averaging $841.64, reflecting positive outlook from multiple investment firms.
• Axon Enterprise reported earnings of $2.12 per share, exceeding analyst expectations, while its quarterly revenue grew by 32.6% year-over-year, reaching $668.54 million.

Ethic Inc. grew its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 90.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,865 shares of the biotechnology company's stock after acquiring an additional 2,315 shares during the period. Ethic Inc.'s holdings in Axon Enterprise were worth $3,982,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. LaSalle St. Investment Advisors LLC grew its stake in shares of Axon Enterprise by 2.1% during the first quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company's stock valued at $408,000 after acquiring an additional 16 shares in the last quarter. Hemington Wealth Management grew its stake in Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 17 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Axon Enterprise by 5.0% in the first quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company's stock worth $203,000 after purchasing an additional 18 shares in the last quarter. WCM Investment Management LLC grew its stake in Axon Enterprise by 0.8% in the first quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company's stock worth $1,306,000 after purchasing an additional 19 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC grew its stake in Axon Enterprise by 0.5% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 3,561 shares of the biotechnology company's stock worth $1,873,000 after purchasing an additional 19 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AXON has been the topic of several research reports. Wolfe Research initiated coverage on Axon Enterprise in a research report on Monday, July 7th. They set an "outperform" rating on the stock. Zacks Research lowered Axon Enterprise from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 2nd. JMP Securities reissued a "market outperform" rating and set a $825.00 price target on shares of Axon Enterprise in a research report on Monday, September 29th. JPMorgan Chase & Co. upped their price target on Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a research report on Thursday, July 17th. Finally, Craig Hallum raised shares of Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 target price on the stock in a report on Tuesday, August 5th. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $841.64.

Axon Enterprise Stock Up 2.2%

Shares of Axon Enterprise stock opened at $716.39 on Friday. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The business's 50 day simple moving average is $733.54 and its 200-day simple moving average is $722.15. The stock has a market capitalization of $56.24 billion, a price-to-earnings ratio of 176.89, a PEG ratio of 27.23 and a beta of 1.41. Axon Enterprise, Inc has a twelve month low of $422.38 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.58. The business had revenue of $668.54 million for the quarter, compared to analysts' expectations of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business's quarterly revenue was up 32.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. Equities research analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Activity at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 77 shares of Axon Enterprise stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $760.00, for a total transaction of $58,520.00. Following the sale, the chief accounting officer owned 15,003 shares of the company's stock, valued at approximately $11,402,280. The trade was a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the sale, the director directly owned 1,416 shares in the company, valued at approximately $1,065,596.64. This trade represents a 6.60% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,932 shares of company stock valued at $45,115,616. Company insiders own 4.40% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.